Induction chemotherapy in head and neck cancer: Closer to an answer?

The Lancet Oncology

Volumn 12, Issue 2, 2011, Pages 113-114

  Corry, June ^a   Rischin, Danny ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; FLUOROURACIL;

CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HEAD AND NECK CANCER; HUMAN; LETTER; LOW DRUG DOSE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 79151483333     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70293-X     Document Type: Letter

References (7)

1. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007, 357:1705-1715. for the TAX 324 Study Group.
2. Lorch JH, Goloubeva O, Haddad RI, et al. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol 2011, for the TAX 324 Study Group, published online Jan 12. 10.1016/S1470-2045(10)70279-5.
3. Pignon JP, Bourhis J, Domenge C, Designé L Chemotherapy added to loco-regional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 2000, 355:949-955. on behalf of the MACH-NC Collaborative Group.
4. Vermorken JB, Remenar E, van Harpen C, et al. Cisplatin, fluorouracil and docetaxel in unresectable head and neck cancer. N Engl J Med 2007, 357:1695-1704. for the EORTC 2947 1/TAX 323 Study Group.
5. Kies MS, Holsinger FC, Lee JJ, et al. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol 2010, 28:8-14.
6. Settle K, Posner MR, Schumaker LM, et al. Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients. Cancer Prev Res 2009, 2:776-781.
7. Posner MR, Lorch JH, Goloubeva O, et al. Oropharynx cancer (OPC) in TAX 324: human papillomavirus (HPV) and survival. Proc Am Soc Clin Oncol 2010, 28:5525. (abstr).